GLYC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GLYC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-06-13), GlycoMimetics's Intrinsic Value: Projected FCF is $-6.64. The stock price of GlycoMimetics is $0.263. Therefore, GlycoMimetics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for GlycoMimetics's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of GlycoMimetics was 62.04. The lowest was 14.62. And the median was 38.33.
The historical data trend for GlycoMimetics's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | -3.29 | -4.53 | -6.36 | -7.27 | -6.34 |
GlycoMimetics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | -6.26 | -5.92 | -6.07 | -6.34 | -6.64 |
For the Biotechnology subindustry, GlycoMimetics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, GlycoMimetics's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where GlycoMimetics's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get GlycoMimetics's Free Cash Flow(6 year avg) = $-45.50.
GlycoMimetics's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Mar24) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.919945764728 | * | -45.4976 | + | 28.911 | * | 0.8) | / | 64.457 | |
= | -6.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics (NAS:GLYC) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
GlycoMimetics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 0.263 | / | -6.6432648808553 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of GlycoMimetics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Edwin Rock | officer: Chief Medical Officer | 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Brian M. Hahn | officer: CFO | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
Daniel M Junius | director | C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Bruce S Johnson | officer: SVP & Chief Commercial Officer | 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850 |
Chinmaya Rath | officer: SVP and Chief Business Officer | 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850 |
Invus Public Equities, L.p. | 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Invus Public Equities Advisors, Llc | 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Artal Group S.a. | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Artal International S.c.a. | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
S.a. Westend | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Administratiekantoor Westend Stichting | 10 percent owner | CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD |
Artal International Management S.a. | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Amaury Wittouck | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661 |
Scott D Sandell | 10 percent owner | |
Harout Semerjian | director, officer: Chief Executive Officer | 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950 |
From GuruFocus
By Business Wire • 08-02-2023
By Business Wire • 11-09-2023
By Business Wire • 08-17-2023
By Business Wire Business Wire • 03-01-2023
By Business Wire Business Wire • 02-16-2023
By Business Wire Business Wire • 12-12-2022
By Business Wire Business Wire • 05-03-2023
By GuruFocus Research • 11-03-2023
By Business Wire • 09-06-2023
By Business Wire Business Wire • 03-29-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.